{
    "clinical_study": {
        "@rank": "16563", 
        "arm_group": [
            {
                "arm_group_label": "Rifampin Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Itraconazole Arm", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, two-arm, drug interaction study will investigate the effect of\n      co-administration of rifampin or itraconazole on the pharmacokinetics of GDC-003 2 in\n      healthy volunteers. In Arm A, volunteers will receive GDC-0032 and rifampin\n\n      ; in Arm B, volunteers will receive GDC-0032 and itraconazole. The anticipated t ime on\n      study treatment is approximately 30 days."
        }, 
        "brief_title": "A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female volunteers will be non-pregnant, non-lactating, and either postmenopausal for\n             at least 1 year or surgically sterile\n\n          -  Male volunteers will either be sterile, or agree to use adequate methods of\n             contraception\n\n          -  Body mass index (BMI) range 18 to 32 kg/m2, inclusive\n\n          -  No clinically significant findings from medical history, physical examination,\n             12-lead ECG, vital signs; and clinical laboratory evaluations\n\n          -  Negative hepatitis B virus, hepatitis C virus and negative HIV antibody screens\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical manifestation of any significant metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,\n             gastrointestinal, neurological, or psychiatric disorder\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance\n\n          -  History of stomach or intestinal surgery or resection that would alter absorption\n             and/or excretion of orally administered study drugs\n\n          -  History of alcoholism or drug addiction within 1 year prior to Check-in\n\n          -  History of chronic proton pump inhibitor (PPI) use within 6 months of Check-in, or\n             use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to Check-in\n             and during the entire study\n\n          -  Clinically significant history of liver disease, including viral or other hepatitis,\n             current alcohol abuse, or cirrhosis\n\n          -  History type 1 or 2 diabetes and/or elevated fasting glucose at baseline\n\n          -  Malabsorption syndrome or other condition that would interfere with enteral\n             absorption\n\n          -  Use of any tobacco- or nicotine containing- products\n\n          -  Participation in any other investigational study drug or biologic agent trial in\n             which receipt of an investigational study drug occurred within 5 half-lives or 30\n             days, whichever is longer to Check-in and during the entire study duration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814709", 
            "org_study_id": "GP28617"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Rifampin Arm", 
                    "Itraconazole Arm"
                ], 
                "description": "Oral doses of GDC-0032", 
                "intervention_name": "GDC-0032", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rifampin Arm", 
                "description": "Oral doses of Rifampin", 
                "intervention_name": "Rifampin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Itraconazole Arm", 
                "description": "Oral doses of Itraconazole", 
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rifampin", 
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Plasma concentrations of GDC-0032", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}